The estimated Net Worth of Karen J Wilson is at least $6.1 million dollars as of 11 May 2018. Ms. Wilson owns over 3,760 units of Vaxart Inc stock worth over $14,812 and over the last 16 years she sold VXRT stock worth over $6,080,413. In addition, she makes $0 as Independent Director at Vaxart Inc.
Karen has made over 19 trades of the Vaxart Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently she sold 3,760 units of VXRT stock worth $620,400 on 11 May 2018.
The largest trade she's ever made was exercising 36,993 units of Vaxart Inc stock on 11 January 2012 worth over $1,015,828. On average, Karen trades about 2,563 units every 49 days since 2009. As of 11 May 2018 she still owns at least 15,757 units of Vaxart Inc stock.
You can see the complete history of Ms. Wilson stock trades at the bottom of the page.
Karen J. Wilson serves as Independent Director of the Company. She is currently the Senior Vice President, Finance of Jazz Pharmaceuticals plc (“Jazz Pharmaceuticals”). She previously served as Vice President, Finance and Principal Accounting Officer of Jazz Pharmaceuticals and its predecessor company (Jazz Pharmaceuticals, Inc.) beginning in 2011. Ms. Wilson currently is also an independent Director for Angion Biomedica Board of Directors since April 2020. From 2009 to January 2011, she served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc., a biotechnology company. From 2005 to 2009, she served as a principal at the consulting firm Wilson Crisler LLC. Prior to that, from 2001 to 2004, she was Chief Financial Officer of ViroLogic, Inc., a biosciences company. Prior to joining ViroLogic, Ms. Wilson served as Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc. from 1999 to 2001. Prior to 1999, Ms. Wilson worked for Deloitte & Touche LLP for ten years, serving clients in both the life sciences and technology fields. Ms. Wilson is a Certified Public Accountant in the State of California and received a B.S. in Business from the University of California, Berkeley.
Karen Wilson is 57, she's been the Independent Director of Vaxart Inc since 2020. There are 8 older and 5 younger executives at Vaxart Inc. The oldest executive at Vaxart Inc is Anne VanLent, 72, who is the Independent Director.
Karen's mailing address filed with the SEC is C/O VAXART, INC., 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 7 years, insiders at Vaxart Inc have traded over $322,706,538 worth of Vaxart Inc stock and bought 8,979,091 units worth $2,899,807 . The most active insiders traders include Capital, Llc Armistice Capi..., Steven Lo et Wouter Latour. On average, Vaxart Inc executives and independent directors trade stock every 57 days with the average trade being worth of $1,309,363. The most recent stock trade was executed by W. Mark Watson on 18 June 2024, trading 20,000 units of VXRT stock currently worth $13,600.
since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.
Vaxart Inc executives and other stock owners filed with the SEC include: